Brought to you by 
CANbridge gets rights to Aveo's mAb AV203
Mar 2016
Executive Summary
Aveo Pharmaceuticals Inc. (also known as Aveo Oncology) granted CANbridge Life Sciences Ltd. exclusive rights to develop and sell its anticancer monoclonal antibody AV203 worldwide excluding the US, Canada, and Mexico. Biogen Idec previously held an option to the project under a 2009 deal, but waived its option in 2014.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Intra-Biotech Deal
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CANbridge gets rights to Aveo's mAb AV203
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice